Clinical significance of human papillomavirus genotype by linear array assay in Japanese women with uterine cervical lesions and type 16 physical status by in situ hybridization

International Journal of Gynecological Cancer

Volumn 19, Issue 8, 2009, Pages 1396-1401

  Futai, Mizuho ^a   Watanabe, Jun ^a   Jobo, Toshiko ^a   Tsunoda, Shinpei ^a   Nishimura, Yukari ^a   Watanabe, Kayoko ^b   Okayasu, Isao ^a   Unno, Nobuya ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Roch Diagnostics Japan   (Japan)

Author keywords

Carcinoma; Cervical intraepithelial neoplasia; HPV genotype; In situ hybridization; Linear array hybridization

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 71; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN TISSUE; IN SITU HYBRIDIZATION; JAPANESE; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 73349103131     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181b661a4     Document Type: Article

References (21)

1. Health and Welfare Statistics Association. Annual mortality trends by leading cause of death in Japan (1899-2003). J Health Welfare Stat. 2005;52:362-385.
2. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55: 244-265. (Pubitemid 34293391)
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
4. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
5. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324:17-27.
6. Asato T, Maehama T, Nagai Y, et al. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis. 2004;189:1829-1832.
7. Sasagawa T, BashaW, Yamazaki H, et al. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev. 2001;10:45-52.
8. Inoue M, Sakaguchi J, Sasagawa T, et al. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer. 2006;16:1007-1013.
9. Gravitt PE, Peyton CL, Apple RJ, et al. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36:3020-3027.
10. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357-361.
11. Evans MF, Mount SL, Beatty BG, et al. Biotinyl-tyramideYbased in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol. 2002; 15:1339-1347.
12. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
13. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a world wide perspective. J Natl Cancer Inst. 1995;87:796-802.
14. Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus. Best Pract Res Clin Obstet Gynaecol. 2001;15: 677-700.
15. Giuliani L, Coletti A, Syrjanen K, et al. Comparison of DNA sequencing and Roche linear array in human papillomavirus (HPV) genotyping. Anticancer Res. 2006;26:3939-3941.
16. van Hamont D, van Ham MAPC, Bakkers JMJE, et al. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol. 2006;44:3122-3129.
17. Guo M, Sneige N, Silva EG, et al. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol. 2007;20:256-266.
18. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-105.
19. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98:303-315.
20. Chan PKS, Li WH, Chan MYM, et al. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol. 1999;59:232-238.
21. Oh YL, Shin KJ, Han J, et al. Significance of high-risk human papillomavirus detection by polymerase chain reaction in primary cervical cancer screening. Cytopathology. 2001;12:75-83.